Analysis of immune checkpoint inhibitors for advanced non-small cell lung cancer in patients receiving antacids-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Analysis of immune checkpoint inhibitors for advanced non-small cell lung cancer in patients receiving antacids

Published:2024-11 Issue:6 Volume:62 Page:951-959
ISSN:2212-5345
Container-title:Respiratory Investigation
language:en
Short-container-title:Respiratory Investigation

Author:

Isono Taisuke^ORCID,Furuno Hajime,Onodera Yoko,Maruyama Tomoya,Takeuchi Yuki,Ayaka Kojima ,Nishida Takashi,Kobayashi Yoichi,Ishiguro Takashi^ORCID,Takaku Yotaro,Kurashima Kazuyoshi^ORCID,Kagiyama Naho

Publisher

Elsevier BV

Reference32 articles.

1. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer;Gandhi;N Engl J Med,2018

2. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer;Paz-Ares;N Engl J Med,2018

3. Nivolumab plus ipilimumab in advanced non-small-cell lung cancer;Hellmann;N Engl J Med,2019

4. First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial;Paz-Ares;Lancet Oncol,2021

5. Durvalumab with or without tremelimumab in combination with chemotherapy as first-line therapy for metastatic non-small-cell lung cancer: the phase III POSEIDON study;Johnson;J Clin Oncol,2023

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP